Molecular Mechanism of Qingzaojiufei Decoction in the Treatment of Pulmonary Fibrosis based on Network Pharmacology and Molecular Docking

被引:0
作者
Zhao, Yilong [1 ]
Liu, Bohao [1 ]
Li, Yixing [1 ]
Chen, Zhe [1 ]
Zhu, Xingzhuo [1 ]
Tao, Runyi [1 ]
Wang, Zhiyu [1 ]
Wang, Hongyi [1 ]
Zhang, Yanpeng [1 ]
Yan, Shuguang [2 ]
Gong, Qiuyu [1 ]
Zhang, Guangjian [1 ]
机构
[1] Xi An Jiao Tong Univ, Dept Thorac Surg, Affiliated Hosp 1, Xian 710061, Shaanxi, Peoples R China
[2] Shaanxi Univ Chinese Med, Coll Basic Med, Century Ave, Xianyang 712046, Peoples R China
关键词
Qingzaojiufei decoction; pulmonary fibrosis; network pharmacology; molecular docking; TCMSP; protein-protein interaction; MESENCHYMAL TRANSITION; HIF-1-ALPHA; PATHWAYS; PARAQUAT; CELLS; MAPK;
D O I
10.2174/1381612829666230911105931
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: In recent years, pulmonary fibrosis (PF) has increased in incidence and prevalence. Qingzaojiufei decoction (QD) is a herbal formula that is used for the treatment of PF.Objective: In this research, network pharmacology and molecular docking methods were used to explore the major chemical components and potential mechanisms of QD in the treatment of PF.Methods: The principal components and corresponding protein targets of QD were used to screen on Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), Traditional Chinese Medicine Integrated Database (TCMID) and high-throughput experiment-and reference-guided database (HERB), Cytoscape 3.7.2 was used to construct the drug-component-target network. PF targets were collected by GeneCards and Online Mendelian Inheritance in Man (OMIM) databases. The protein-protein interaction (PPI) network was constructed by importing compound-disease intersection targets into the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database and visualized by Cytoscape3.7.2. We further performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis on the intersecting targets. In the last, we validated the core targets and active compounds by molecular docking.Results: The key compounds of quercetin, (-)-epigallocatechin-3-gallate, and kaempferol of QD were obtained. The key targets of AKT1, TNF, and IL6 of QD were obtained. The molecular docking results show that quercetin, (-)-epigallocatechin-3-gallate and kaempferol work well with AKT1, TNF and IL6.Conclusion: This research shows the multiple active components and molecular mechanism of QD in the treatment of PF and offers resources and suggestions for future studies.
引用
收藏
页码:2161 / 2176
页数:16
相关论文
共 60 条
[21]   The arachidonic acid metabolite 11,12-epoxyeicosatrienoic acid alleviates pulmonary fibrosis [J].
Kim, Hak Su ;
Moon, Su-Jin ;
Lee, Sang Eun ;
Hwang, Gi Won ;
Yoo, Hyun Ju ;
Song, Jin Woo .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2021, 53 (05) :864-874
[22]   PubChem 2019 update: improved access to chemical data [J].
Kim, Sunghwan ;
Chen, Jie ;
Cheng, Tiejun ;
Gindulyte, Asta ;
He, Jia ;
He, Siqian ;
Li, Qingliang ;
Shoemaker, Benjamin A. ;
Thiessen, Paul A. ;
Yu, Bo ;
Zaslavsky, Leonid ;
Zhang, Jian ;
Bolton, Evan E. .
NUCLEIC ACIDS RESEARCH, 2019, 47 (D1) :D1102-D1109
[23]   Macrophage Akt1 Kinase-Mediated Mitophagy Modulates Apoptosis Resistance and Pulmonary Fibrosis [J].
Larson-Casey, Jennifer L. ;
Deshane, Jessy S. ;
Ryan, Alan J. ;
Thannickal, Victor J. ;
Carter, A. Brent .
IMMUNITY, 2016, 44 (03) :582-596
[24]   Idiopathic Pulmonary Fibrosis [J].
Lederer, David J. ;
Martinez, Fernando J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19) :1811-1823
[25]  
Lei Ling, 2016, Clin Exp Rheumatol, V34 Suppl 100, P14
[26]   Network pharmacology prediction and molecular docking-based strategy to explore the potential mechanism of Huanglian Jiedu Decoction against sepsis [J].
Li, Xing ;
Wei, Shizhang ;
Niu, Shengqi ;
Ma, Xiao ;
Li, Haotian ;
Jing, Manyi ;
Zhao, Yanling .
COMPUTERS IN BIOLOGY AND MEDICINE, 2022, 144
[27]   Anti-PD-L1 antibody alleviates pulmonary fibrosis by inducing autophagy via inhibition of the PI3K/Akt/mTOR pathway [J].
Lu, Ye ;
Zhong, Wenshan ;
Liu, Yuanyuan ;
Chen, Weimou ;
Zhang, Jinming ;
Zeng, Zhaojin ;
Huang, Haohua ;
Qiao, Yujie ;
Wan, Xuan ;
Meng, Xiaojing ;
Cai, Shaoxi ;
Dong, Hangming .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 104
[28]   Idiopathic pulmonary fibrosis [J].
Martinez, Fernando J. ;
Collard, Harold R. ;
Pardo, Annie ;
Raghu, Ganesh ;
Richeldi, Luca ;
Selman, Moises ;
Swigris, Jeffrey J. ;
Taniguchi, Hiroyuki ;
Wells, Athol U. .
NATURE REVIEWS DISEASE PRIMERS, 2017, 3
[29]   Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis [J].
Meyer, Keith C. .
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2017, 11 (05) :343-359
[30]   Akt1 regulates pulmonary fibrosis via modulating IL-13 expression in macrophages [J].
Nie, Yunjuan ;
Hu, Yudong ;
Yu, Kaikai ;
Zhang, Dan ;
Shi, Yinze ;
Li, Yaolin ;
Sun, Lei ;
Qian, Feng .
INNATE IMMUNITY, 2019, 25 (07) :451-461